Blood test to predict chemo and immunotherapy response in stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether a blood test (called immune proteomics) can predict how well chemotherapy and immunotherapy work in people with stomach cancer. If you qualify, you would receive standard chemo or chemo plus immunotherapy before surgery, and researchers will study your blood to see if it can guide future treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been newly diagnosed with stomach cancer (gastric adenocarcinoma).
- Your tumor is in the stomach or where the stomach meets the esophagus and is at a certain stage (T3-4, no spread to distant organs).
- Your doctors think you can have chemo or chemo plus immunotherapy before surgery, and that surgery can likely remove all the cancer.
- You have not had any other cancer treatment for this disease, and you haven't had certain treatments like steroids or blood transfusions recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses advanced testing to predict how well stomach cancer responds to chemotherapy combined with immunotherapy. It may help find the best treatment for advanced or metastatic stomach or gastroesophageal junction cancer that hasn't been treated yet.
This study looks at stomach (or stomach–esophagus junction) cancer tissue, treatment details, and patient-reported experiences to better predict how you may respond to standard chemotherapy. It may help personalize future treatment by identifying markers that connect your tumor environment and your expected outcomes.
This trial uses a combination of CT scans, ultrasound, and blood tests to predict how well chemotherapy will work for people with locally advanced gastric cancer. The goal is to personalize treatment by identifying who will respond best to neoadjuvant chemotherapy.
This trial studies whether blood tests before treatment can predict side effects from immunotherapy (PD-1/PD-L1 inhibitors) in people with gastric cancer. If you are about to start this type of treatment, your participation could help doctors manage side effects better.
This trial uses artificial intelligence to analyze CT scans, blood, and tumor tissue to predict how well your cancer will respond to chemotherapy and immunotherapy before surgery. It aims to personalize treatment for locally advanced stomach or gastroesophageal junction cancer.
This study looks for ways to predict whether neoadjuvant chemotherapy (chemo given before surgery) will work well in people with locally advanced stomach cancer. It may help doctors choose the best treatment plan sooner based on your test results.
Hear when a new Gastric Cancer, Gastroesophageal Junction Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.